Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HCP0816
- Development stage
- Unknown
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HCP0816 is a pharmaceutical-grade omega-3-acid ethyl ester product developed by Hanmi Pharmaceutical for the treatment of hyperlipidemia. It functions as a lipid-regulating agent that primarily lowers serum triglyceride levels by reducing hepatic production of very-low-density lipoproteins (VLDL) and enhancing the clearance of triglycerides from the blood. In clinical development, HCP0816 has been evaluated in Phase 1 pharmacokinetic studies, often in comparison with or as a component of fixed-dose combinations like HCP1105 (rosuvastatin/omega-3) to optimize treatment regimens for patients with mixed dyslipidemia.
- Other names
- omega-3-acid ethyl estersomega3-acid ethyl estersomega 3-acid ethyl esters
Beyond the preview
Go deeper on HCP0816.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HCP0816.